TOVX · Insider Trading
Theriva Biologics, Inc.
Every open-market purchase and sale reported by TOVX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-06 | Jeffrey J Kraws | Director | A | +75,000 deriv. | — |
| 2026-01-06 | Steven A Shallcross | CEO and CFO | A | +475,000 deriv. | — |
| 2026-01-06 | John J Monahan | Director | A | +75,000 deriv. | — |
| 2026-01-06 | Jeffrey Alan Wolf | Director | A | +75,000 deriv. | — |
| 2025-05-01 | Steven A Shallcross | CEO and CFO | A | +190,000 deriv. | — |
| 2025-05-01 | Jeffrey Alan Wolf | Director | A | +25,000 deriv. | — |
| 2025-05-01 | John J Monahan | Director | A | +25,000 deriv. | — |
| 2025-05-01 | Jeffrey J Kraws | Director | A | +25,000 deriv. | — |
| 2023-12-15 | Jeffrey Alan Wolf | Director | A | +110,000 deriv. | — |
| 2023-12-15 | Jeffrey J Kraws | Director | A | +110,000 deriv. | — |
| 2023-12-15 | John J Monahan | Director | A | +110,000 deriv. | — |
| 2023-12-15 | Steven A Shallcross | CEO and CFO | A | +700,000 deriv. | — |
| 2023-06-08 | Steven A Shallcross | CEO and CFO | Buy | +14,000 | +$9.70K |
| 2023-06-07 | Steven A Shallcross | CEO and CFO | Buy | +26,000 | +$16.45K |
| 2023-02-13 | Steven A Shallcross | CEO and CFO | Buy | +25,000 | +$26.07K |
| 2023-02-03 | Steven A Shallcross | CEO and CFO | Buy | +25,000 | +$23.51K |
| 2023-01-26 | Steven A Shallcross | CEO and CFO | Buy | +25,000 | +$21.82K |
| 2023-01-23 | Steven A Shallcross | CEO and CFO | Buy | +25,000 | +$18.70K |
| 2023-01-03 | Steven A Shallcross | CEO and CFO | Buy | +100,000 | +$43.70K |
| 2022-12-16 | Jeffrey J Kraws | Director | A | +100,000 deriv. | — |
| 2022-12-16 | Steven A Shallcross | CEO and CFO | A | +475,000 deriv. | — |
| 2022-12-16 | Francis Tufaro | Chief Operating Officer | A | +100,000 deriv. | — |
| 2022-12-16 | Jeffrey Alan Wolf | Director | A | +100,000 deriv. | — |
| 2022-12-16 | John J Monahan | Director | A | +100,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Steven A Shallcross | CEO and CFO | 10,000 | $1.95K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TOVX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.